MULTIPLE MYELOMA

During a live event, Naresh Bumma, MD, discussed CRS, oral and skin toxicities, and low discontinuation rates with talquetamab in multiple myeloma.

C. Ola Landgren, MD, PhD, discusses the feedback he received on minimal residual disease at this year’s Miami Myeloma MRD Meeting in April.

In a 6 to 2 vote, the Oncologic Drug Advisory Committee determined that findings from the phase 3 AQUILA trial do support a positive benefit-risk ratio for patients with smoldering multiple myeloma.

In an interview with Targeted Oncology, C. Ola Langren, MD, PhD, discussed the continuing impact of the groundbreaking FDA ODAC vote, the future of the Miami Myeloma MRD Meeting, and how researchers plan to continue expanding the role of MRD in myeloma and other hematologic malignancies.

Ashraf Z. Badros, MBChB, discussed the results from the AURIGA trial of maintenance therapy with daratumumab and lenalidomide in newly diagnosed multiple myeloma.

In the last year, there has been excitement about the use of MRD in multiple myeloma trials and new approaches to assessing clinical outcomes in patients.

In separate live virtual events, Sarah A. Holstein, MD, PhD, and Shashank Cingam, MD, discuss options for a patient with relapsed/refractory multiple myeloma and the use of chimeric antigen receptor (CAR) T-cell therapy.

Praneeth Reddy Sudalagunta, PhD, discusses a novel generative artificial intelligence pipeline developed to help with the understanding and treatment of multiple myeloma.

During a live event, Jack Khouri, MD, discusses selinexor-based therapies for relapsed multiple myeloma, emphasizing AE management and weekly dosing.

Ciara Freeman, MD, PhD, discusses the challenges of incorporating anito-cel into the treatment protocol for patients with multiple myeloma.

Ciara Freeman, MD, PhD, discusses anito-cel's unique functions and benefits for treating multiple myeloma.

Jack Khouri, MD, discusses data from a multicenter study of teclistamab in patients with relapsed/refractory multiple myeloma who had prior exposure to BCMA-directed therapy.

During a live event, Kathleen A. Dorritie, MD, discussed updated outcomes from the IsKia, MASTER, and CONCEPT clinical trials of frontline therapy in multiple myeloma.

Following promising phase 1 data, ISB 2001 has gained fast track designation from the FDA for the treatment of relapsed/refractory multiple myeloma.

The final ALCYONE analysis with 86.7-month follow-up shows daratumumab-VMP significantly improved overall survival in transplant-ineligible, newly diagnosed multiple myeloma.

Douglas Sborov, MD, discusses adverse events in the MajesTEC-1 study of teclistamab in multiple myeloma.

During a live event, Naresh Bumma, MD, discussed talquetamab’s efficacy in relapsed/refractory multiple myeloma, including high-risk patients.

During a live event, Jack Khouri, MD, discussed options for patients with multiple myeloma after relapse and choices to consider before CAR T-cell therapy.

During a live event, Kathleen A. Dorritie, MD, discussed updated outcomes from the GRIFFIN and PERSEUS clinical trials of quadruplet therapy in multiple myeloma.

Melphalan flufenamide (melflufen) is approved in Europe for relapsed/refractory multiple myeloma, but the FDA withdrew its approval of the treatment last year.

John M. Burke, MD, highlights findings from the AQUILA, DREAMM 7, and MajesTEC-5 trials in multiple myeloma.

A real-world study has reinforced the efficacy and safety of teclistamab in heavily pretreated patients with relapsed/refractory multiple myeloma.

In a live virtual event, Attaya Suvannasankha, MD, discussed the MajesTEC-1 trial of teclistamab and approaches to mitigation of cytokine release syndrome.

Marc Raab, MD, PhD, discussed the MajesTEC-5 trial of teclistamab plus standard myeloma therapies in transplant-eligible newly diagnosed multiple myeloma.

During a live event, Patrick Moore, MD, discussed the KarMMa-3 subgroup analyses and quality of life for patients with relapsed/refractory multiple myeloma.